Immunotherapy
From the Journals
Connective tissue diseases reported in patients receiving immune checkpoint inhibitors
For the first time, new-onset connective tissue disease has been reported in patients who were treated with anti-PD1/PDL-1 agents, according to...
Conference Coverage
Nivolumab shows promise for pretreated advanced HCC
SAN FRANCISCO – Nivolumab was associated with durable responses in heavily pretreated patients with advanced hepatocellular carcinoma in the dose-...
Conference Coverage
Nivolumab effective in PD-L1–deficient lung cancers
A detailed analysis of nivolumab’s performance in a pivotal trial with non–small cell lung cancer patients showed similar efficacy to docetaxel...
Conference Coverage
Nivolumab safe, effective for salvage in advanced gastric cancer
The human monoclonal IgG4 antibody nivolumab was safe and effective as a salvage treatment for patients in a randomized phase III trial who failed...
Conference Coverage
VIDEO: Improved QOL an added benefit of pembrolizumab for NSCLC patients
First-line treatment of selected non–small-cell lung cancer patients with pembrolizumab produced significantly better quality of life, compared...
Conference Coverage
Oncolytic virus active against bladder cancer
For patients with non-muscle invasive bladder cancer, intravesicular administration of an oncolytic virus was both feasible and safe, and in a...
Conference Coverage
Vaccine/PD-1 inhibitor combo shows early promise against mCRPC
National Harbor, MD. – To date, checkpoint inhibitors have shown little clinical activity as single agents against metastatic, castration-...